Key strengths include a high-margin product base, positive net income and free cash flow, strong liquidity with net cash, and a clear leadership position in complement C3 inhibition backed by deep scientific expertise and a meaningful patent estate. The company’s two commercial products address serious unmet needs and provide a solid commercial platform for future growth and pipeline expansion.

Main risks center on thin overall profitability due to heavy operating and R&D costs, substantial accumulated historical losses, and dependence on a small number of closely related products. Competitive and regulatory pressures in high-cost specialty therapies, potential safety or reimbursement challenges, and the inherent uncertainty of clinical development all pose material threats to its long-term financial and strategic trajectory.

Apellis appears to be in a transitional phase from a cash-consuming biotech to a self-sustaining commercial platform company. If it can grow revenue from its existing products, secure successful label expansions, and bring pipeline programs to market while gradually improving operating efficiency, its current financial and scientific position provides a solid foundation. However, the path ahead is execution-heavy and exposed to clinical, competitive, and policy uncertainties, so future results may be uneven even if the long-term opportunity in complement-mediated diseases remains attractive.